Log in to save to my catalogue

Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China

Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4d0af3324e6e4c21a5db8711ee29c45a

Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China

About this item

Full title

Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China

Publisher

Cheshire: Springer Healthcare

Journal title

Infectious diseases and therapy, 2023-11, Vol.12 (11), p.2595-2609

Language

English

Formats

Publication information

Publisher

Cheshire: Springer Healthcare

More information

Scope and Contents

Contents

Introduction
A pan-genotypic and effective treatment regimen for patients with chronic hepatitis C virus (HCV) infection remains an unmet medical need in China. Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor in development for the treatment of chronic HCV infection. We conducted a phase 3 study to evaluate the efficacy and safety of...

Alternative Titles

Full title

Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_4d0af3324e6e4c21a5db8711ee29c45a

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4d0af3324e6e4c21a5db8711ee29c45a

Other Identifiers

ISSN

2193-8229

E-ISSN

2193-6382

DOI

10.1007/s40121-023-00872-4

How to access this item